Wave Life Sciences Ltd (WVE)

Form 8-K - Current report

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral...

Wave Life Sciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May...

Form 8-K - Current report

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable...

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...

Form DEF 14A - Other definitive proxy statements

Form PRER14A - Preliminary Proxy Soliciting materials

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA...

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...